Transcode Therapeutics Inc (RNAZ) - News Archive

Unlocking the Secrets of MicroRNA: TransCode Therapeutics Journey Toward Combatting Metastatic Cancer In the ever-evolving world of biotech innovation, TransCode Therapeutics is making bold strides with its groundbreaki...

: TransCode Therapeutics has announced the successful initiation of its Phase 1 clinical trial, marking a significant milestone in the field of RNA-based therapeutics. This trial explores the safety and efficacy of the...

TransCode Therapeutics, an innovative biotech company, has recently announced the publication of several pivotal studies revealing the profound potential of its lead therapeutic candidate, TTX-MC138, in combating metast...

TransCode Therapeutics Inc. a clinical-stage biopharmaceutical company focusing on developing RNA-targeted therapeutics for cancer treatment, has recently been awarded a $2 million grant from the National Institutes of...

TransCode Therapeutics Continues to Secure Funding for Innovative RNA Oncology Treatments: Impact on Shareholders and FinancialsIn recent news, TransCode Therapeutics, a clinical-stage RNA oncology company, has made sig...

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has recently released its financial report for the third quarter of 2024, showcasing positive developments in its cash and quick ratio. As a clinical-stage RNA oncology compan...

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage RNA oncology company, has recently announced the successful closure of its public offering, generating approximately $8.5 million in gross proceeds. The comp...

In the ever-evolving world of pharmaceuticals, Transcode Therapeutics Inc (RNAZ) has emerged as a player to watch. Despite facing challenges and market fluctuations, the company has maintained its commitment to revoluti...

The field of oncology has seen remarkable advancements in recent years, particularly with the emergence of RNA therapeutics. Among the notable contributors in this area is TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an...

:TransCode Therapeutics, a prominent biopharmaceutical company specializing in the development of innovative therapies, has recently reported positive pre-clinical results for its lead candidate, TTX-MC138. This groundb...

TransCode Therapeutics, a leading RNA oncology company, is set to unveil exciting new data from the Phase 0 clinical trial of its revolutionary RNA therapeutic, TTX-MC138. As the company s lead candidate in cancer thera...

TransCode Therapeutics Raises $9.7 Million in Capital to Accelerate Breakthroughs in RNA OncologyTransCode Therapeutics, a leading RNA oncology company dedicated to transforming cancer treatment through innovative RNA t...

In a promising move towards developing more effective cancer treatments, TransCode Therapeutics, Inc. (Nasdaq: RNAZ) revealed today that it has entered into a definitive securities purchase agreement for the sale and pu...

TransCode Therapeutics Closes $8.5 Million Public Offering, Focusing on Advancing RNA Therapeutics in Cancer TreatmentTransCode Therapeutics, Inc. (Nasdaq: RNAZ) has successfully closed its public offering, generating a...